Logo wahanariau.com
  2. Junshi biosciences

Junshi biosciences

Index
Globenewswire

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Senin, 08 Desember 2025 - 21:43:47 Wib
Globenewswire

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

Senin, 08 Desember 2025 - 21:42:57 Wib
Globenewswire

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Rabu, 26 November 2025 - 04:08:26 Wib
Globenewswire

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

Sabtu, 18 Oktober 2025 - 04:25:16 Wib
Globenewswire

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

Senin, 08 September 2025 - 22:36:36 Wib
Globenewswire

Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates

Rabu, 27 Agustus 2025 - 23:15:08 Wib
Globenewswire

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Sabtu, 09 Agustus 2025 - 00:56:21 Wib
Globenewswire

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

Selasa, 27 Mei 2025 - 19:30:00 Wib
Globenewswire

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

Jumat, 25 April 2025 - 21:50:09 Wib
Globenewswire

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

Sabtu, 29 Maret 2025 - 22:23:41 Wib
Globenewswire

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Jumat, 28 Maret 2025 - 02:09:02 Wib
Globenewswire

Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma

Senin, 24 Maret 2025 - 22:53:00 Wib
Globenewswire

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

Senin, 20 Januari 2025 - 20:55:22 Wib
Globenewswire

Junshi Biosciences Announces Toripalimab’s Approval in Australia

Jumat, 17 Januari 2025 - 18:00:00 Wib
Globenewswire

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

Sabtu, 16 November 2024 - 15:30:00 Wib
Globenewswire

Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR

Selasa, 15 Oktober 2024 - 18:00:00 Wib
Globenewswire

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

Rabu, 25 September 2024 - 12:00:00 Wib
Globenewswire

Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

Sabtu, 31 Agustus 2024 - 21:34:41 Wib
Globenewswire

Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Senin, 12 Agustus 2024 - 21:00:00 Wib
Globenewswire

Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab

Jumat, 26 Juli 2024 - 22:00:00 Wib
Globenewswire

Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Kamis, 18 Juli 2024 - 12:00:00 Wib
Globenewswire

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC

Selasa, 25 Juni 2024 - 21:25:11 Wib
Globenewswire

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Rabu, 19 Juni 2024 - 05:14:29 Wib
Globenewswire

Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

Kamis, 13 Juni 2024 - 08:55:27 Wib
Globenewswire

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Jumat, 26 April 2024 - 03:48:28 Wib